Cost of illness coronavirus disease 2019 (covid-19) with comorbidities in a hospital in west java
##plugins.themes.academic_pro.article.sidebar##
Downloads
##plugins.themes.academic_pro.article.main##
Abstract
Epidemiological evidence has suggested that individuals with chronic disease may have a 10-fold risk of developing severe COVID-19 disease compared to individuals without comorbidities. The analysis that estimates the cost of treating COVID-19 patients is still very limited, especially in Indonesia. Thus, in this study, disease costs will be carried out to analyze the costs of clinical management of COVID-19 in patients with comorbidities during hospitalization. This study is a descriptive study using the economy evaluation method, in which the burden of the economy of the COVID-19 disease is included in the direct costs. Sampling was carried out with a purposive sampling method in inpatient COVID-19 patients who had comorbidities at a hospital in West Java during the second wave of COVID-19 in Indonesia (June, July, and August 2021). Ninety-six patients were diagnosed with COVID-19 with comorbid CAP and comorbid Type 2 DM, whose cost data were evaluated with the cost of illness. The total cost of COVID-19 patients with comorbid CAP is Rp. 1,773,944,688 with an average cost of Rp. 25,342,067 ± 10,550,734, and comorbid type 2 diabetes is Rp. 782,391,792 with an average cost of Rp. 30,091,992 ± 14,773,533. The average length of stay for COVID-19 patients with comorbid CAP was 10.1 ± 3.6 days, and comorbid type 2 DM was 11.3 ± 4.5 days. These results indicate that COVID-19 with comorbidities provides a considerable burden on patients, increases the length of treatment for patients, and is quite expensive.
##plugins.themes.academic_pro.article.details##
References
da Costa Sousa, V., da Silva, M. C., de Mello, M. P., Guimarães, J. A. M., & Perini, J. A. (2022). Factors associated with mortality, length of hospital stay and diagnosis of COVID-19: Data from a field hospital. Journal of Infection and Public Health, 15(7), 800–805. https://doi.org/10.1016/j.jiph.2022.06.010
Fidler, S., Stöhr, W., Pace, M., Dorrell, L., Lever, A., Pett, S., Kinloch-de Loes, S., Fox, J., Clarke, A., Nelson, M., Thornhill, J., Khan, M., Fun, A., Bandara, M., Kelly, D., Kopycinski, J., Hanke, T., Yang, H., Bennett, R., … Murray, T. (2020). Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. The Lancet, 395(10227), 888–898. https://doi.org/10.1016/S0140-6736(19)32990-3
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., … Zhong, N. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720. https://doi.org/10.1056/nejmoa2002032
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Ismaila, H., Asamani, J. A., Lokossou, V. K., Oduro-Mensah, E., Nabyonga-Orem, J., & Akoriyea, S. K. (2021). The cost of clinical management of SARS-COV-2 (COVID-19) infection by level of disease severity in Ghana: a protocol-based cost of illness analysis. BMC Health Services Research, 21(1). https://doi.org/10.1186/s12913-021-07101-z
Jeck, J., Jakobs, F., Kron, A., Franz, J., Cornely, O. A., & Kron, F. (2022). A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. Infection, 50(1), 191–201. https://doi.org/10.1007/s15010-021-01685-8
Jin, H., Wang, H., Li, X., Zheng, W., Ye, S., Zhang, S., Zhou, J., & Pennington, M. (2021). Economic burden of covid-19, china, january–march, 2020: A cost-of-illness study. Bulletin of the World Health Organization, 99(2), 112–124. https://doi.org/10.2471/BLT.20.267112
Liang, W. H., Guan, W. J., Li, C. C., Li, Y. M., Liang, H. R., Zhao, Y., Liu, X., Sang, L., Sang, L., Chen, R. C., Tang, C. L., Wang, T., Wang, W., He, Q. H., Chen, Z. S., Wong, S. S., Zanin, M., Liu, J., Xu, X., … He, J. X. (2020). Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): A nationwide analysis of China. European Respiratory Journal, 55(6). https://doi.org/10.1183/13993003.00562-2020
Mohamed, M. S., Moulin, T. C., & Schiöth, H. B. (2021). Sex differences in COVID-19: the role of androgens in disease severity and progression. In Endocrine (Vol. 71, Issue 1, pp. 3–8). Springer. https://doi.org/10.1007/s12020-020-02536-6
Nakhaei, K., Jalilian, H., Arab-Zozani, M., Heydari, S., Torkzadeh, L., & Taji, M. (2021). Direct and indirect cost of COVID-19 patients in Iran. Health Policy and Technology, 10(4). https://doi.org/10.1016/j.hlpt.2021.100572
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., Paniz-Mondolfi, A., Lagos-Grisales, G. J., Ramírez-Vallejo, E., Suárez, J. A., Zambrano, L. I., Villamil-Gómez, W. E., Balbin-Ramon, G. J., Rabaan, A. A., Harapan, H., … Sah, R. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. In Travel Medicine and Infectious Disease (Vol. 34). Elsevier USA. https://doi.org/10.1016/j.tmaid.2020.101623
Sharifi, N., & Ryan, C. J. (2020). Editorial: Androgen hazards with COVID-19. In Endocrine-Related Cancer (Vol. 27, Issue 6, pp. E1–E3). BioScientifica Ltd. https://doi.org/10.1530/ERC-20-0133
Wambier, C. G., Goren, A., Vaño-Galván, S., Ramos, P. M., Ossimetha, A., Nau, G., Herrera, S., & McCoy, J. (2020). Androgen sensitivity gateway to COVID-19 disease severity. In Drug Development Research (Vol. 81, Issue 7, pp. 771–776). Wiley-Liss Inc. https://doi.org/10.1002/ddr.21688